Analyzing Biomerica (BMRA) & Its Competitors

Biomerica (NASDAQ:BMRA) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Biomerica to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.

Insider & Institutional Ownership

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 12.3% of Biomerica shares are owned by company insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Biomerica and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1	0	0	0	1.00
Biomerica Competitors	4284	10561	18340	830	2.46

Biomerica presently has a consensus target price of $9.00, suggesting a potential upside of 480.65%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 19.12%. Given Biomerica’s higher probable upside, research analysts plainly believe Biomerica is more favorable than its rivals.

Profitability

This table compares Biomerica and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomerica	-115.50%	-142.81%	-77.83%
Biomerica Competitors	-276.78%	-149.08%	-21.73%

Earnings and Valuation

This table compares Biomerica and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biomerica	$4.45 million	-$3.78 million	-0.95
Biomerica Competitors	$1.88 billion	$139.14 million	12.55

Biomerica’s rivals have higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Biomerica has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Biomerica’s rivals have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Summary

Biomerica rivals beat Biomerica on 9 of the 12 factors compared.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.